Protagonist Therapeutics (PTGX) EBIT Margin (2017 - 2026)

Protagonist Therapeutics has disclosed EBIT Margin across 10 years of filings, most recently posting 6.47% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 6.47%, up 6171.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 192.36% (down 10978.0% YoY), and the FY2025 annual result was 343.63%, down 35714.0% from the prior year.
• EBIT Margin came in at 6.47% for Q1 2026 at Protagonist Therapeutics, up from 677.09% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 192189.47% in Q4 2022 to a low of 4824.56% in Q2 2022.
• The 5-year median for EBIT Margin is 82.07% (2022), against an average of 14154.73%.
• Across the five-year window, EBIT Margin jumped 19261904 bps in 2022 and tumbled 19118826 bps in 2023, its largest moves.
• Protagonist Therapeutics' EBIT Margin stood at 192189.47% in 2022, then slumped by 99 bps to 1001.21% in 2023, then tumbled by 104 bps to 40.84% in 2024, then tumbled by 1558 bps to 677.09% in 2025, then surged by 99 bps to 6.47% in 2026.
• The last three EBIT Margin figures came in at 6.47% (Q1 2026), 677.09% (Q4 2025), and 985.17% (Q3 2025), per Business Quant data.